US clears first ‘living drug’ for tough childhood leukemia – Chicago Tribune
|
US clears first ‘living drug’ for tough childhood leukemia
Chicago Tribune Opening a new era in cancer care, the Food and Drug Administration on Wednesday approved the first treatment that genetically engineers patients’ own blood cells into an army of assassins to seek and destroy childhood leukemia. The CAR–T cell treatment … |
Maine Public |
FDA Approves First Gene Therapy Treatment For Cancer
Maine Public The Food and Drug Administration Wednesday announced what the agency calls a “historic action” — the first approval of a gene therapy in the United States. The FDA approved Kymriah, which scientists refer to as a “living drug” because it involves … |
|
‘Historic Action’: FDA Approves First CAR–T Therapy
Regulatory Focus In addition to Kymriah’s approval, FDA also announced the expanded approval of Roche’s Actemra (tocilizumab) to treat CAR T-cell-induced severe or life-threatening cytokine release syndrome in patients 2 years of age or older. “In clinical trials in … |
KRVS |
FDA Approves First Gene Therapy Treatment For Cancer
KRVS The Food and Drug Administration Wednesday announced what the agency calls a “historic action” — the first approval of a gene therapy in the United States. The FDA approved Kymriah, which scientists refer to as a “living drug” because it involves … |
GenomeWeb |
Let the CRISPR Games Begin! | GenomeWeb
GenomeWeb Researchers at the Stanford University School of Medicine have launched a new level for the online computer game Eterna, in which they’re asking players to … Researchers challenge video game players to design CRISPR …UPI.com |
KASU |
FDA Approves First Gene Therapy Treatment For Cancer
KASU The Food and Drug Administration Wednesday announced what the agency calls a “historic action” — the first approval of a gene therapy in the United States. The FDA approved Kymriah, which scientists refer to as a “living drug” because it involves … |
Cancer Therapy Advisor |
FDA Approves CAR–T Therapy Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia
Cancer Therapy Advisor This approval marks the first chimeric antigen receptor T cell (CAR-T) therapy, which utilizes the patients’ own genetically-modified T–cells to target the CD19 antigen on the surface of leukemia cells. Once modified, the cells are injected back into … |
Cancer Therapy Advisor |
FDA Approves CAR–T Therapy Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia
Cancer Therapy Advisor This approval marks the first chimeric antigen receptor T cell (CAR-T) therapy, which utilizes the patients’ own genetically-modified T–cells to target the CD19 antigen on the surface of leukemia cells. Once modified, the cells are injected back into … |